Evercore Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$784K Buy
1,257
+3
+0.2% +$2.04K 0.01% 245
2026
Q1
$969K Buy
1,254
+75
+6% +$57.4K 0.02% 220
2025
Q4
$910K Sell
1,179
-12
-1% -$8.15K 0.01% 223
2025
Q3
$670K Sell
1,191
-160
-12% -$90.5K 0.01% 257
2025
Q2
$709K Sell
1,351
-22
-2% -$12.3K 0.01% 244
2025
Q1
$871K Buy
1,373
+71
+5% +$48.8K 0.01% 230
2024
Q4
$927K Sell
1,302
-3
-0.2% -$2.52K 0.01% 224
2024
Q3
$1.37M Hold
1,305
0.02% 194
2024
Q2
$1.37M Hold
1,305
0.02% 191
2024
Q1
$1.26M Sell
1,305
-153
-10% -$145K 0.02% 199
2023
Q4
$1.28M Sell
1,458
-1
-0.1% -$823 0.02% 200
2023
Q3
$1.2M Sell
1,459
-47
-3% -$36.9K 0.02% 198
2023
Q2
$1.08M Sell
1,506
-106
-7% -$81.7K 0.02% 208
2023
Q1
$1.32M Sell
1,612
-28
-2% -$21.1K 0.03% 186
2022
Q4
$1.18M Buy
1,640
+173
+12% +$128K 0.02% 194
2022
Q3
$1.01M Buy
1,467
+195
+15% +$123K 0.02% 201
2022
Q2
$752K Sell
1,272
-6
-0.5% -$3.9K 0.02% 230
2022
Q1
$893K Sell
1,278
-18
-1% -$11.4K 0.02% 237
2021
Q4
$819K Sell
1,296
-45
-3% -$27.7K 0.01% 248
2021
Q3
$812K Sell
1,341
-150
-10% -$93.1K 0.01% 237
2021
Q2
$833K Sell
1,491
-3
-0.2% -$1.52K 0.02% 245
2021
Q1
$707K Buy
1,494
+145
+11% +$70.6K 0.01% 254
2020
Q4
$651K Buy
1,349
+63
+5% +$34K 0.01% 258
2020
Q3
$719K Sell
1,286
-3
-0.2% -$1.82K 0.02% 227
2020
Q2
$804K Sell
1,289
-9
-0.7% -$5.11K 0.02% 216
2020
Q1
$634K Buy
1,298
+135
+12% +$55.7K 0.02% 216
2019
Q4
$437K Hold
1,163
0.01% 294
2019
Q3
$322K Sell
1,163
-203
-15% -$60.1K 0.01% 326
2019
Q2
$427K Sell
1,366
-188
-12% -$62.6K 0.01% 292
2019
Q1
$638K Buy
1,554
+17
+1% +$7K 0.02% 244
2018
Q4
$574K Sell
1,537
-7
-0.5% -$2.56K 0.02% 239
2018
Q3
$624K Sell
1,544
-76
-5% -$28.9K 0.02% 253
2018
Q2
$559K Sell
1,620
-20
-1% -$6.25K 0.02% 258
2018
Q1
$565K Sell
1,640
-139
-8% -$48.3K 0.02% 232
2017
Q4
$669K Hold
1,779
0.02% 227
2017
Q3
$795K Buy
1,779
+20
+1% +$9.52K 0.03% 198
2017
Q2
$864K Sell
1,759
-109
-6% -$47.7K 0.03% 194
2017
Q1
$724K Sell
1,868
-130
-7% -$48.2K 0.03% 217
2016
Q4
$734K Sell
1,998
-319
-14% -$121K 0.03% 212
2016
Q3
$932K Sell
2,317
-335
-13% -$134K 0.04% 183
2016
Q2
$926K Buy
2,652
+152
+6% +$58.5K 0.04% 180
2016
Q1
$901K Buy
2,500
+244
+11% +$101K 0.04% 181
2015
Q4
$1.23M Buy
2,256
+345
+18% +$187K 0.06% 164
2015
Q3
$892K Sell
1,911
-7
-0.4% -$3.76K 0.04% 190
2015
Q2
$979K Buy
1,918
+533
+38% +$260K 0.04% 200
2015
Q1
$625K Buy
1,385
+340
+33% +$144K 0.03% 245
2014
Q4
$429K Buy
1,045
+92
+10% +$36.2K 0.02% 262
2014
Q3
$345K Buy
953
+140
+17% +$46.9K 0.02% 316
2014
Q2
$230K Buy
813
+60
+8% +$17.8K 0.01% 368
2014
Q1
$226K Buy
753
+455
+153% +$140K 0.01% 353
2013
Q4
$83K Sell
298
-11,260
-97% -$3.24M ﹤0.01% 482
2013
Q3
$3.61M Buy
11,558
+98
+0.9% +$25.8K 0.21% 117
2013
Q2
$2.58M Buy
+11,460
New +$2.67M 0.15% 141

Other funds holding REGN

Evercore Wealth Management's REGN Position: Q2 2026 in Review

Evercore Wealth Management increased its Regeneron Pharmaceuticals (REGN) stake by 0.24% in Q2 2026, buying an estimated $2.04K and bringing the position to 1,257 shares worth $784K. The position accounts for 0.01% of the portfolio, ranked #245.

Evercore Wealth Management first reported a position in REGN in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.61M in Q3 2013. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Evercore Wealth Management held 1,257 shares of Regeneron Pharmaceuticals worth $784K as of Q2 2026.
  • Evercore Wealth Management bought 3 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.04K.
  • Regeneron Pharmaceuticals made up 0.01% of Evercore Wealth Management's portfolio in Q2 2026, its #245 holding.
  • Evercore Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
  • Evercore Wealth Management's Regeneron Pharmaceuticals position peaked at $3.61M in Q3 2013.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Evercore Wealth Management's 13F filing for Q2 2026, filed 14 Aug 2026.